Gilead (GILD) Achieves 100% Rate with Sofosbuvir, Ledipasvir Combo on HCV
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $143.72 -0.75%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Join SI Premium – FREE
Gilead (Nasdaq: GILD) sofosbuvir and ledipasvir combo said to achieve 100 percent SVR-12, curing all of the hep-C (HCV) patients in recent study. The combo was administered to treatment naive and null responders. The trial was conducted with 34 HCV patients.
Data were presented at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands.
Shares are up 2 percent on the session.
Data were presented at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands.
Shares are up 2 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) PT Raised to $175 at HSBC
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- FDA approves Scholar Rock's ISEMBYLD for spinal muscular atrophy
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
